Opipza Film, Soluble
Product Images NDC 15370-403

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Opipza (NDC 15370-403). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carwin Pharmaceutical Associates, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Opipza 01)

FDA Label Image

Figure 1 (Opipza 02)

Figure 1 (Opipza 02)
This text provides information on the effect of various drugs on Aripiprazole. It mentions inhibitors and inducers of different CYP enzymes along with their respective drugs. The text also includes a chart showing the change in Aripiprazole levels and corresponding confidence intervals when interacting with other drugs.*
FDA Label Image

Figure 2 (Opipza 03)

Figure 2 (Opipza 03)
Not available.*
FDA Label Image

Figure 3 (Opipza 04)

Figure 3 (Opipza 04)
This text provides information on the effect of Aripiprazole on other drugs, specifically mentioning the potential interactions with various medications such as dextromethorphan, warfarin, valproate, and tiagabine. It also includes data on fold change and confidence intervals related to these drug interactions.*
FDA Label Image

Figure 4 (Opipza 05)

FDA Label Image

Figure 5 (Opipza 06)

FDA Label Image

Figure 6 (Opipza 07)

Figure 6 (Opipza 07)
This text provides data on the proportion with relapse for Aripiprazole compared to Placebo, along with the number of subjects at risk and the days from randomization. The information can be used in a study or analysis on relapse rates between the two groups.*
FDA Label Image

Figure 7 (Opipza 08)

Figure 7 (Opipza 08)
This data appears to show the least-squares mean change in the YGTSS Total TIC Score over the weeks of treatment with Aripiprazole (low and high doses) compared to placebo. The chart displays a change in the YGTSS Total TIC Score from baseline.*
FDA Label Image

Figure A (Opipza 09)

FDA Label Image

Figure B (Opipza 10)

FDA Label Image

Figure C (Opipza 11)

FDA Label Image

Figure D (Opipza 12)

FDA Label Image

Figure E (Opipza 13)

FDA Label Image

Principal Display Panel (2 mg Film Pouch Carton)

Principal Display Panel (2 mg Film Pouch Carton)
This is a product label for aripiprazole oral film. It comes in 30 pouches, with each pouch containing 1 oral film. The pharmacist is instructed to dispense the enclosed Medication Guide to each patient. It is specified not to cut or chew the oral film. The label includes the NDC code 15370-401-30 and mentions that it is for prescription use only. Additionally, there is barcode and lot number information provided at the bottom.*
FDA Label Image

Principal Display Panel (5 mg Film Pouch Carton)

Principal Display Panel (5 mg Film Pouch Carton)
This is a pharmaceutical product label for Aripiprazole oral film, with instructions not to cut or chew the film. Each package contains 30 pouches, each containing 1 oral film. The pharmacist is advised to dispense the enclosed Medication Guide to each patient. The label also includes the NDC number 15370-402-30.*
FDA Label Image

Principal Display Panel (10 mg Film Pouch Carton)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.